Healthcare Triangle, Inc. — Form 8-K Summary
Reporting event: Nasdaq delisting notice received October 1, 2026; the report was signed October 2, 2026. This filing reports a listing-compliance matter, not periodic financial results.
Business context and financial information
The filing identifies Healthcare Triangle, Inc. as a Delaware corporation whose common stock trades on Nasdaq under HCTI. It provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics, and no comparable-period figures.
Nasdaq listing notice and material developments
- Nasdaq notified the company that its common stock does not meet the minimum $1.00 closing bid-price requirement under Listing Rule 5550(a)(2).
- The company is ineligible for the usual 180-day compliance period because it completed a 1-for-249 reverse split on August 1, 2025, and a 1-for-60 reverse split on February 10, 2026. Nasdaq cites the combined 1-for-14,940 ratio over the prior two years.
- Nasdaq issued a Staff Delisting Determination. Unless the company requests a hearing by October 8, 2026, trading is set to be suspended at the opening of business on October 12, 2026, followed by a Form 25-NSE filing to remove the securities from Nasdaq listing and registration.
- The company says it intends to request a hearing. A timely request would stay the suspension and Form 25-NSE filing pending the Panel’s decision and any additional extension it grants. The stock continues to trade under HCTI in the interim.
Outlook, risks, and unusual items
The company intends to present a plan to regain bid-price compliance, which may include another reverse stock split. There is no assurance that the Panel will grant continued listing or that the company will regain compliance within any additional period allowed. The filing also refers investors to risk factors in the company’s Form 10-K filed April 15, 2026, as amended, and other SEC filings.
Key facts for investors to verify
- Whether the company submitted its Nasdaq hearing request by October 8, 2026, and the Panel’s decision and any resulting deadlines.
- Whether Nasdaq trading was suspended or the company’s securities were delisted, and whether HCTI’s trading venue or status changed.
- Any announced compliance plan, including whether another reverse stock split is proposed or completed.
- Current financial condition and operating performance, which are not detailed in this 8-K.